agilon health, inc. Share-based Payment Arrangement, Expense
agilon health, inc. (AGL) reported Share-based Payment Arrangement, Expense of $13.26 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2024-11-07
- agilon health, inc. share-based payment arrangement, expense for the quarter ending 2024-09-30 was $13.26M, a 35.70% decline year-over-year.
- agilon health, inc. share-based payment arrangement, expense for the quarter ending 2024-06-30 was $18.21M, a 6.37% decline year-over-year.
- agilon health, inc. share-based payment arrangement, expense for the quarter ending 2024-03-31 was $16.91M, a 24.47% increase year-over-year.
- agilon health, inc. share-based payment arrangement, expense for the quarter ending 2023-12-31 was $15.68M, a 62.63% increase year-over-year.
- agilon health, inc. share-based payment arrangement, expense for fiscal 2023 was $69.33M, a 146.98% increase from fiscal 2022.
- agilon health, inc. share-based payment arrangement, expense for fiscal 2022 was $28.07M, a 90.38% decline from fiscal 2021.
- agilon health, inc. share-based payment arrangement, expense for fiscal 2021 was $291.67M, a 4406.67% increase from fiscal 2020.
- agilon health, inc. share-based payment arrangement, expense for fiscal 2020 was $6.47M, a 47.12% increase from fiscal 2019.
| Period end | Share-based Payment Arrangement, Expense 1 month | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 9 month as first filed | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | $13.26M 10-Q · filed 2024-11-07 | $31.47M derived: sum of 2 quarters · filed 2024-11-07 | $48.38M 10-Q · filed 2024-11-07 | $64.05M derived: sum of 4 quarters · filed 2024-11-07 | |||||
| 2024-06-30 | $18.21M 10-Q · filed 2024-08-06 | $35.12M 10-Q · filed 2024-08-06 | $50.79M derived: sum of 3 quarters · filed 2024-08-06 | $71.41M derived: sum of 4 quarters · filed 2024-11-07 | |||||
| 2024-03-31 | $16.91M 10-Q · filed 2024-05-07 | $32.59M derived: sum of 2 quarters · filed 2024-05-07 | $53.20M derived: sum of 3 quarters · filed 2024-11-07 | $72.65M derived: sum of 4 quarters · filed 2024-11-07 | |||||
| 2023-12-31 | $15.68M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $36.30M derived: sum of 2 quarters · filed 2024-11-07 | $55.74M derived: sum of 3 quarters · filed 2024-11-07 | $69.33M 10-K · filed 2024-02-27 | |||||
| 2023-09-30 | $20.62M 10-Q · filed 2024-11-07 | $20.74M 10-Q · filed 2023-11-02 | $40.06M derived: sum of 2 quarters · filed 2024-11-07 | $53.65M 10-Q · filed 2024-11-07 | $53.98M 10-Q · filed 2023-11-02 | $63.29M derived: sum of 4 quarters · filed 2024-11-07 | |||
| 2023-06-30 | $19.45M 10-Q · filed 2024-08-06 | $19.57M 10-Q · filed 2023-08-03 | $33.03M 10-Q · filed 2024-08-06 | $33.24M 10-Q · filed 2023-08-03 | $42.67M derived: sum of 3 quarters · filed 2024-08-06 | $50.58M derived: sum of 4 quarters · filed 2024-08-06 | |||
| 2023-03-31 | $13.59M 10-Q · filed 2024-05-07 | $13.67M 10-Q · filed 2023-05-09 | $23.22M derived: sum of 2 quarters · filed 2024-05-07 | $31.13M derived: sum of 3 quarters · filed 2024-05-07 | $37.68M derived: sum of 4 quarters · filed 2024-05-07 | ||||
| 2022-12-31 | $9.64M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $17.55M derived: sum of 2 quarters · filed 2024-02-27 | $24.10M derived: sum of 3 quarters · filed 2024-02-27 | $28.07M 10-K · filed 2024-02-27 | $28.38M 10-K · filed 2023-03-01 | ||||
| 2022-09-30 | $7.91M 10-Q · filed 2023-11-02 | $14.46M derived: sum of 2 quarters · filed 2023-11-02 | $18.43M 10-Q · filed 2023-11-02 | $22.12M derived: sum of 4 quarters · filed 2024-02-27 | |||||
| 2022-06-30 | $6.55M 10-Q · filed 2023-08-03 | $10.52M 10-Q · filed 2023-08-03 | $14.21M derived: sum of 3 quarters · filed 2024-02-27 | $26.18M derived: sum of 4 quarters · filed 2024-02-27 | |||||
| 2022-03-31 | $3.97M 10-Q · filed 2023-05-09 | $7.66M derived: sum of 2 quarters · filed 2024-02-27 | $19.62M derived: sum of 3 quarters · filed 2024-02-27 | $294.17M derived: sum of 4 quarters · filed 2024-02-27 | |||||
| 2021-12-31 | $3.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $15.65M derived: sum of 2 quarters · filed 2024-02-27 | $290.20M derived: sum of 3 quarters · filed 2024-02-27 | $291.67M 10-K · filed 2024-02-27 | $292.39M 10-K · filed 2022-03-03 | ||||
| 2021-09-30 | $11.96M 10-Q · filed 2022-11-03 | $286.51M derived: sum of 2 quarters · filed 2022-11-03 | $287.98M 10-Q · filed 2022-11-03 | $289.72M derived: sum of 4 quarters · filed 2023-03-01 | |||||
| 2021-06-30 | $274.55M 10-Q · filed 2022-08-04 | $276.02M 10-Q · filed 2022-08-04 | $277.76M derived: sum of 3 quarters · filed 2023-03-01 | $279.32M derived: sum of 4 quarters · filed 2023-03-01 | |||||
| 2021-04-30 | $2.60M 10-K · filed 2024-02-27 | ||||||||
| 2021-03-31 | $1.47M 10-Q · filed 2022-05-05 | $3.21M derived: sum of 2 quarters · filed 2023-03-01 | $4.77M derived: sum of 3 quarters · filed 2023-03-01 | $6.92M derived: sum of 4 quarters · filed 2023-03-01 | |||||
| 2020-12-31 | $1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $3.30M derived: sum of 2 quarters · filed 2023-03-01 | $5.45M derived: sum of 3 quarters · filed 2023-03-01 | $6.47M 10-K · filed 2023-03-01 | |||||
| 2020-09-30 | $1.56M 10-Q · filed 2021-10-28 | $3.71M derived: sum of 2 quarters · filed 2021-10-28 | $4.73M 10-Q · filed 2021-10-28 | ||||||
| 2020-06-30 | $2.15M 10-Q · filed 2021-08-04 | $3.18M 10-Q · filed 2021-08-04 | |||||||
| 2019-12-31 | $4.40M 10-K · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |